Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
about
Compromised redox homeostasis, altered nitroso-redox balance, and therapeutic possibilities in atrial fibrillationThe Current Role of Omega-3 Fatty Acids in the Management of Atrial FibrillationEvaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic SubstrateOmega-3 supplements and cardiovascular diseasesDo omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trialsFish oil and post-operative atrial fibrillation: a meta-analysis of randomized controlled trialsRationale and current perspective for early rhythm control therapy in atrial fibrillation.Atrial fibrillation: inflammation in disguise?Fish, fish-derived n-3 fatty acids, and risk of incident atrial fibrillation in the Atherosclerosis Risk in Communities (ARIC) studyA meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation.Fish, Marine n-3 Fatty Acids, and Atrial Fibrillation - Experimental Data and Clinical EffectsEffect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation.The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and designNovel pharmacological targets for the rhythm control management of atrial fibrillation.The effects of supplementation with omega-3 polyunsaturated Fatty acids on cardiac rhythm: anti-arrhythmic, pro-arrhythmic, both or neither? It depends…Omega-3 Fatty acids: anti-arrhythmic, pro-arrhythmic, or both?Dietary omega-3 fatty acids and susceptibility to ventricular fibrillation: lack of protection and a proarrhythmic effect.Why Do We Still Need Large Scale Clinical Trial: The Case of n-3 PUFA.Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation.How Are n-3 LCPUFAs Antiarrhythmic? A Reassessment of n-3 LCPUFAs in Cardiac Disease.Polyunsaturated Fatty acids in atrial fibrillation: looking for the proper candidates.A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids for Inhibition of Supraventricular Arrhythmias After Cardiac Surgery: The FISH Trial.Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions.Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?Association between use of specialty dietary supplements and C-reactive protein concentrations.Omega 3 and atrial fibrillation: Where are we?N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Do Omega-3 Fatty Acids Decrease the Incidence of Atrial Fibrillation?Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation in Patients with Atrial Fibrillation.Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation.Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and InterventionsOmega-3 fatty acids: mechanisms underlying 'protective effects' in atherosclerosis.Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.Advances in cardiology: clinical trial update.
P2860
Q26770909-AD7A6189-877F-4CE1-97A4-504D83D2C789Q26781534-E4F2354B-595C-4366-A5DF-CC40DB08DF56Q26799163-03BCDF1A-E5E1-46A7-B923-D17883E509F0Q26864908-B8C10D43-E304-4C2E-B690-144ABFE375DEQ27021408-38381472-8D3F-4B92-88C7-E122B5A30A1DQ27026646-85E0AA51-18A7-4C40-AD4E-768391B1120AQ27692632-DD5D4784-0E31-428B-9A6F-98B9B5709D42Q27693290-C8E738D3-60A5-4350-AE92-CA76749A9111Q34263408-0333EC13-D1A9-4478-A271-0DB7ED16B7ADQ34278784-9918E0E2-07FE-4AAE-ACFE-F555EC5E262DQ34288835-73918547-3DC3-4134-A2AF-9739EC49DD8BQ34771487-69EB4255-6AD4-4762-8780-5A6FAA88963EQ35100790-C94BE438-4AD2-453F-9D18-8E8D82A35831Q35489060-E44D5709-3337-4A5D-836A-469C8311557AQ35865078-F48CB4B2-456D-40C3-965D-3B033E42B1D1Q35892876-279B8956-22EE-467D-97CE-4EE756C38936Q36049390-964EE64E-C6CB-4169-9ACB-A62B917D75B4Q36064570-84E84919-4799-4D80-AD7D-B0DE9D2348CAQ36193817-6DDDD305-3DC7-4DD9-A274-23F7F102D7AAQ36199969-59624495-4572-4BBB-8FBB-95F6E2030122Q36254295-EC1603F3-9F07-4F4A-BF8D-B725BE4DF0DAQ36366168-8159A603-12BB-4FCE-A974-5DF9CF12EC41Q36382360-95E52F8A-5CB5-4714-B69E-F15D08BAC2F7Q36518152-C6F28C1B-CC4E-45CF-8A03-1B568C9BF85BQ36606633-47E11E69-A761-45EA-A97A-A1D1DADCAE46Q36615207-E0B6E411-3D28-4A57-9BF2-AD85B6D214B1Q36701732-6D44B7E2-2F19-48BF-8820-D5F724AB991EQ36960923-D8848FD3-8014-4418-9602-73C16E002B5DQ37066818-C9F71A83-7552-4A60-9CB6-8C46B8B97B74Q37495794-20AE4F39-C673-44F9-A1D9-CE83031CA2FAQ37495989-D527D402-69FD-4C38-A10F-553528ACDF21Q37496071-F5C6958D-DCC8-4E90-90BD-7CE0B50E8437Q37496128-05F82530-8919-4B77-AF5D-34038552BA58Q37496298-36CF35E5-757B-4101-A251-AD70EC4DF1FDQ37496314-FB4DB869-85DB-4ED1-AFBD-69F84F931677Q37571905-4AB7DB5B-DE18-4865-A80B-B7C5EB1D0092Q37649248-714B4C5D-34D0-4C61-AA73-E292422B90D4Q37844891-487BA3BA-20EA-4FE9-8A22-12D5639D6D59Q37868371-4E4FCED3-47E2-4291-B2E5-8E18DAEF6B86Q37882706-939E2995-42D4-4A83-A79B-3905D47B25CE
P2860
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Efficacy and safety of prescri ...... a randomized controlled trial.
@en
type
label
Efficacy and safety of prescri ...... a randomized controlled trial.
@en
prefLabel
Efficacy and safety of prescri ...... a randomized controlled trial.
@en
P2093
P356
P1476
Efficacy and safety of prescri ...... a randomized controlled trial.
@en
P2093
Craig M Pratt
Gerald V Naccarelli
James A Reiffel
Kenneth A Ellenbogen
Peter R Kowey
P304
P356
10.1001/JAMA.2010.1735
P407
P577
2010-11-15T00:00:00Z